DBP International AB: The EC/CA submission for SI-053 has been sent to the Netherlands
Double Bond Pharmaceutical International AB (publ) ("DBP") takes another step towards the start of the phase 1 multinational multicentral clinical trial of its front-line product SI-053 in patients with glioblastoma - the Ethical Committee/Competent Authority submissions for SI-053 in The Netherlands has also been sent.As previously was reported the Clinical Trial Application (CTA) was sent and the CTA concerned 3 sites in Germany. With the current submission in the Netherlands DBP adds additionally a site for the trial. The process